Local Anesthetics in Special Populations

LA in Special Groups - The Ground Rules

• Altered pharmacokinetics: Expect changes in absorption, distribution (e.g., altered Vd), metabolism (↓ hepatic/renal clearance), and excretion.
• Altered pharmacodynamics: Nerve sensitivity is often ↑ (e.g., elderly, pregnancy), affecting LA potency/duration.
• Guiding principles:
  • Adopt "start low, go slow" dosing.
  • Crucial: meticulous monitoring for early CNS/CVS toxicity signs.
  • Proactive dose reduction is key.

⭐ Special populations often have a narrower therapeutic window for LAs, demanding careful titration and heightened vigilance.

Pediatric Patients - Tiny Patients, Big Care

• Pharmacokinetic Differences:
  • ↑ Volume of distribution (Vd) (larger Extracellular Fluid).
  • ↓ Protein binding (esp. neonates due to ↓ alpha-1-acid glycoprotein) → ↑ free drug fraction.
  • ↓ Hepatic metabolism (immature P450 enzymes).
  • ↓ Renal excretion (immature Glomerular Filtration Rate).
• Increased Toxicity Risk:
  • Higher susceptibility to systemic toxicity.
  • ⚠️ Prilocaine/Benzocaine: Risk of methemoglobinemia (avoid in infants <6 months).
• Maximum Recommended Doses (mg/kg):

  Anesthetic	Plain	With Epinephrine
  Lidocaine	3-5	5-7
  Bupivacaine	1.5-2	2-2.5
  Ropivacaine	2-3	2-3

⭐ Neonates exhibit decreased levels of alpha-1-acid glycoprotein, leading to a higher free fraction of local anesthetics and an increased risk of toxicity.

Geriatric Patients - Golden Years, Gentle Doses

• Physiological Considerations:
  • Reduced organ function (hepatic, renal) → ↓ LA clearance, ↑ half-life.
  • Decreased lean body mass, increased body fat → ↑ volume of distribution for lipid-soluble LAs.
  • Altered protein binding (↓ albumin) → ↑ unbound, active LA.
  • Increased sensitivity of nervous tissue.
  • Polypharmacy → potential drug interactions.
• Pharmacokinetic Changes:
  • Slower onset of action.
  • Longer duration of effect.
• Dosing Strategy: Reduce dose by 20-50%. Titrate slowly.

⭐ Geriatric patients show increased susceptibility to CNS toxicity (e.g., confusion, agitation) and cardiotoxicity from LAs.

Pregnancy & Lactation - Two Lives, One Plan

Physiological changes: ↑ CO, ↑ GFR, ↑ Vd; ↓ protein binding (↑ free drug).

• ⚠️ Increased sensitivity to LA neurotoxicity & cardiotoxicity (e.g., Bupivacaine).

Placental Transfer:

• Factors: ↑ lipid solubility, ↓ ionization, ↓ protein binding, ↓ molecular weight (📌 LIMP).
• Ion trapping: Fetal acidosis traps LAs (weak bases) in ionized form. $pH - pKa = log([A^-]/[HA])$.

⭐ Progesterone increases neuronal sensitivity to local anesthetics during pregnancy.

LA Safety Profile:

Co-morbid Conditions - Tricky Terrains

High‑Yield Points - ⚡ Biggest Takeaways

• Pregnancy: Bupivacaine has ↑ cardiotoxicity; Lidocaine (Cat B) safer. Avoid high-dose Prilocaine (methemoglobinemia).
• Pediatrics: Neonates: ↓ AAG, immature liver. Use precise weight-based dosing. Max lidocaine 4.5 mg/kg.
• Geriatrics: ↓ clearance necessitates LA dose reduction (e.g., 20-50%).
• Severe Liver Disease: Reduce amide LA dose significantly; ester LAs are safer.
• Renal Failure: Amide LA dose often unchanged; active metabolites may accumulate.
• Pseudocholinesterase Deficiency: Avoid ester LAs (prolonged action); prefer amides.
• Obesity: Dose LAs based on Ideal Body Weight (IBW) to prevent toxicity.